CN114096245A - 作为ccr2/ccr5拮抗剂的杂环烷基类化合物 - Google Patents

作为ccr2/ccr5拮抗剂的杂环烷基类化合物 Download PDF

Info

Publication number
CN114096245A
CN114096245A CN202080045527.XA CN202080045527A CN114096245A CN 114096245 A CN114096245 A CN 114096245A CN 202080045527 A CN202080045527 A CN 202080045527A CN 114096245 A CN114096245 A CN 114096245A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
isomer
acceptable salt
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080045527.XA
Other languages
English (en)
Other versions
CN114096245B (zh
Inventor
罗云富
巴庾勇
陈燕和
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Lingfang Biopharmaceutical Technology Co.,Ltd.
Original Assignee
Shenzhen Lingfang Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Lingfang Biomedical Technology Co ltd filed Critical Shenzhen Lingfang Biomedical Technology Co ltd
Publication of CN114096245A publication Critical patent/CN114096245A/zh
Application granted granted Critical
Publication of CN114096245B publication Critical patent/CN114096245B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明公开了一系列带有杂环烷基结构的化合物、其异构体或其药学上可接受的盐，及其在制备治疗与CCR2/CCR5拮抗剂相关疾病药物中的应用，具体公开了式(Ι)所示化合物或其药学上可接受的盐、其异构体或其药学上可接受的盐。
Figure DDA0003423376200000011

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN202080045527.XA 2019-06-24 2020-06-24 作为ccr2/ccr5拮抗剂的杂环烷基类化合物 Active CN114096245B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910554176 2019-06-24
CN2019105541764 2019-06-24
PCT/CN2020/098222 WO2020259620A1 (zh) 2019-06-24 2020-06-24 作为ccr2/ccr5拮抗剂的杂环烷基类化合物

Publications (2)

Publication Number Publication Date
CN114096245A true CN114096245A (zh) 2022-02-25
CN114096245B CN114096245B (zh) 2023-02-28

Family

ID=74060722

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080045527.XA Active CN114096245B (zh) 2019-06-24 2020-06-24 作为ccr2/ccr5拮抗剂的杂环烷基类化合物

Country Status (7)

Country Link
US (1) US20230002360A1 (zh)
EP (1) EP3988098A4 (zh)
JP (1) JP7292588B2 (zh)
KR (1) KR20220024199A (zh)
CN (1) CN114096245B (zh)
AU (1) AU2020301443B2 (zh)
WO (1) WO2020259620A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113412261A (zh) * 2019-04-08 2021-09-17 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023143112A1 (zh) * 2022-01-26 2023-08-03 无锡瓴方生物医药科技有限公司 氮杂苯并八元环化合物的盐型、晶型及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014105A1 (en) * 2001-08-08 2003-02-20 Takeda Chemical Industries, Ltd. Bicyclic compound, production and use as hiv inhibitors
EP1422228A1 (en) * 2001-08-08 2004-05-26 Takeda Chemical Industries, Ltd. BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
WO2018103757A1 (zh) * 2016-12-09 2018-06-14 广东众生药业股份有限公司 作为ccr2/ccr5受体拮抗剂的联苯化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001058992A (ja) * 1999-06-16 2001-03-06 Takeda Chem Ind Ltd ベンゾアゼピン誘導体、その製造法および用途
JP2003119191A (ja) * 2001-08-08 2003-04-23 Takeda Chem Ind Ltd ベンゾアゼピン誘導体、その製造法および用途
WO2004069834A1 (ja) * 2003-02-07 2004-08-19 Takeda Pharmaceutical Company Limited 三環性化合物、その製造方法および用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014105A1 (en) * 2001-08-08 2003-02-20 Takeda Chemical Industries, Ltd. Bicyclic compound, production and use as hiv inhibitors
EP1422228A1 (en) * 2001-08-08 2004-05-26 Takeda Chemical Industries, Ltd. BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
WO2018103757A1 (zh) * 2016-12-09 2018-06-14 广东众生药业股份有限公司 作为ccr2/ccr5受体拮抗剂的联苯化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TACKE F.: "Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis", 《EXPERT OPINION ON INVESTIGATIONAL DRUGS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113412261A (zh) * 2019-04-08 2021-09-17 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途

Also Published As

Publication number Publication date
JP7292588B2 (ja) 2023-06-19
WO2020259620A1 (zh) 2020-12-30
EP3988098A1 (en) 2022-04-27
CN114096245B (zh) 2023-02-28
KR20220024199A (ko) 2022-03-03
AU2020301443B2 (en) 2023-07-20
JP2022539752A (ja) 2022-09-13
AU2020301443A1 (en) 2022-01-27
US20230002360A1 (en) 2023-01-05
EP3988098A4 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
JP6877407B2 (ja) Ｎｔｒｋ関連障害の治療に有用な化合物および組成物
WO2021259331A1 (zh) 八元含n杂环类化合物
WO2008072682A1 (ja) イミダゾ［１，２－ｂ］ピリダジン誘導体
CN115594734B (zh) 酮酰胺衍生物及其应用
WO2020239076A1 (zh) 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
WO2021057890A1 (zh) 作为crac抑制剂的2h-苯并吡喃衍生物
CN114096245B (zh) 作为ccr2/ccr5拮抗剂的杂环烷基类化合物
KR20200141041A (ko) Trk 키나제 억제제로서의 마크로사이클릭 화합물
CN113993860A (zh) 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物
CN103508931B (zh) 六氢并环戊二烯衍生物、其制备方法及其在医药上的应用
CN114728967A (zh) 作为jak抑制剂的三并杂环类化合物及其应用
CN109867675B (zh) 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
CN110023286B (zh) 作为ccr2/ccr5受体拮抗剂的联苯化合物
CN114478520A (zh) Bcl-2蛋白凋亡诱导剂及应用
CN114008046B (zh) 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
WO2021073593A1 (zh) 作为cdk2/4/6三重抑制剂的氨基嘧啶类化合物
CN112955453B (zh) 作为选择性Trk抑制剂的吡唑并嘧啶衍生物
CN115667247B (zh) 吡啶类衍生物及其应用
CN112752749B (zh) 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物
CN115003672A (zh) 喹啉并咪唑类化合物及其应用
CN113439080A (zh) 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物
CN111971285A (zh) 咪唑并吡咯酮化合物及其应用
CN115872996B (zh) 一种雌激素受体降解剂化合物及其制备方法和应用
WO2021083011A1 (zh) 桥环并醛基吡啶衍生物及其应用
WO2021098810A1 (zh) 用作选择性雄激素受体调节剂的化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: Room 504, Building C1, No. 201 Linghu Avenue, Xinwu District, Wuxi City, Jiangsu Province, 214028

Patentee after: Wuxi Lingfang Biopharmaceutical Technology Co.,Ltd.

Address before: 518045 1312, building 1, Changfu Jinmao building, south of Shihua Road, Fubao community, Fubao street, Futian District, Shenzhen, Guangdong Province

Patentee before: Shenzhen Lingfang Biomedical Technology Co.,Ltd.

CP03 Change of name, title or address